Related Experiment Video
Updated: Jan 23, 2026
12:29
mRNA Interactome Capture from Plant Protoplasts
Published on: July 28, 2017
9.6K
The FUS-DDIT3 Interactome in Myxoid Liposarcoma
Jamie S E Yu1, Shane Colborne2, Christopher S Hughes2
1Department of Pathology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Neoplasia (New York, N.Y.)
|June 21, 2019
Summary
Researchers identified key proteins interacting with the FUS-DDIT3 oncoprotein in myxoid liposarcoma. This discovery offers potential new therapeutic targets, especially for epigenetic drugs, to combat metastatic disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Myxoid liposarcoma is a deep soft tissue cancer with poor outcomes for metastatic disease.
- The FUS-DDIT3 fusion oncoprotein drives myxoid liposarcoma but its mechanism is unclear.
Purpose of the Study:
- To identify functional interacting partners of the FUS-DDIT3 oncoprotein.
- To uncover the molecular mechanisms underlying myxoid liposarcoma development and progression.
Main Methods:
- Immunoprecipitation-mass spectrometry (IP-MS) was used to identify FUS-DDIT3 interacting proteins.
- Quantitative MS and co-immunoprecipitation validated protein-protein interactions.
Main Results:
- The FUS-DDIT3 interactome is enriched with RNA processing proteins.
- FUS-DDIT3 interacts with chromatin regulatory complexes like NuRD, SWI/SNF, PRC1, PRC2, and MLL1.
- Specific interactions with BRG1/SMARCA4, BAF155/SMARCC1, BAF57/SMARCE1, and KDM1A were confirmed.
Conclusions:
- The study identifies novel FUS-DDIT3 interacting partners involved in RNA processing and chromatin regulation.
- These findings provide potential therapeutic targets for myxoid liposarcoma, particularly through epigenetic drug development.
